Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST phase II trial of IMAB362 plus EOX in CLDN18.2-positive advanced gastroesophageal adenocarcinoma
2011-005285-38Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zolbetuximab in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Started Feb 2012; status: terminated.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2011-005285-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005285-38.